RecruitingNot Applicable

Study on Plasmablastic Lymphoma Patients

Italy200 participantsStarted 2025-02-14

Plain-language summary

This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.

Who can participate

Age range15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022 * Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report * Age \> 18 years old * Availability of complete medical records * Availability of histopathological material requested by the study Exclusion Criteria: * Any other histology than PBL * Lack of complete medical records * Lack of histopathological material requested by the study

What they're measuring

Overall Survival (OS)

Timeframe: 36 months

Trial details

NCT IDNCT06781359

SponsorFondazione Italiana Linfomi - ETS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-02-01

Contact for this trial

Uffici Studi FIL

+390131033153 startup@filinf.it

View on ClinicalTrials.gov More Plasmablastic Lymphoma trials